• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

TSC/MTOR 突变型嗜酸性肾肿瘤是一种独特的实体瘤,其 CK7+/CK20-/波形蛋白-:一项验证性研究。

TSC/MTOR-mutated eosinophilic renal tumors are a distinct entity that is CK7+/CK20-/vimentin-: a validation study.

机构信息

Department of Pathology, The University of Chicago, IL, USA.

Department of Pathology, The University of Chicago, IL, USA.

出版信息

Hum Pathol. 2021 Sep;115:84-95. doi: 10.1016/j.humpath.2020.12.006. Epub 2020 Dec 22.

DOI:10.1016/j.humpath.2020.12.006
PMID:33352195
Abstract

Unclassified renal cell carcinoma (RCC) accounts for ∼10% of renal tumors, and the most common histologic finding in these cases is eosinophilic cytoplasm. We previously demonstrated that a subset of eosinophilic renal tumors with heterogeneous morphology and immunohistochemical (IHC) staining harbored pathogenic mutations in tuberous sclerosis complex (TSC) or mammalian target of rapamycin (MTOR) as the primary defining mutation. We identified an additional 8 cases of eosinophilic tumors with unusual morphology that were originally diagnosed as chromophobe RCC (CHRCC) or CHRCC, eosinophilic variant. As a comparison, we included four classic CHRCC cases and one CHRCC, eosinophilic variant case. Gross examination revealed solid or solid and cystic patterns. The solid areas were composed of eosinophilic tumor cells divided by congested vessels, whereas the cystic areas were lined by cytologically bland eosinophilic cells with septae containing nests, ribbons, and single eosinophilic tumor cells. The tumor cells had abundant granular eosinophilic cytoplasm with round nuclei and inconspicuous nucleoli. IHC analysis demonstrated diffuse staining for CK7 and negative staining for CK20 and vimentin. Next-generation sequencing identified pathogenic variants in three genes: TSC1, TSC2, and MTOR. They also lacked significant copy number variations in contrast to our control cases. We have demonstrated with our expanded study that cases previously diagnosed as CHRCC or CHRCC, eosinophilic variant with discordant histology and IHC staining patterns may represent a separate subtype of RCC characterized by mutations in the TSC/MTOR pathway.

摘要

未分类的肾细胞癌(RCC)占肾脏肿瘤的 10%左右,这些病例中最常见的组织学发现是嗜酸性细胞质。我们之前的研究表明,一组具有异质性形态和免疫组织化学(IHC)染色的嗜酸性肾肿瘤,具有结节性硬化复合物(TSC)或哺乳动物雷帕霉素靶蛋白(MTOR)的致病性突变,作为主要的定义突变。我们又鉴定了 8 例形态异常的嗜酸性肿瘤,最初诊断为嫌色细胞 RCC(CHRCC)或嗜酸性变异型。作为比较,我们纳入了 4 例经典 CHRCC 病例和 1 例 CHRCC,嗜酸性变异型病例。大体检查显示实性或实性伴囊性模式。实性区域由被充血血管分隔的嗜酸性肿瘤细胞组成,而囊性区域由细胞学上温和的嗜酸性细胞组成,间隔含有巢、带和单个嗜酸性肿瘤细胞。肿瘤细胞具有丰富的颗粒状嗜酸性细胞质,圆形核,不明显的核仁。免疫组化分析显示 CK7 弥漫性染色,CK20 和波形蛋白阴性染色。下一代测序鉴定出三个基因的致病性变异:TSC1、TSC2 和 MTOR。与我们的对照病例相比,它们也没有明显的拷贝数变异。通过我们的扩展研究表明,以前诊断为 CHRCC 或 CHRCC,嗜酸性变异型,具有不一致的组织学和 IHC 染色模式的病例,可能代表一种由 TSC/MTOR 通路突变特征的 RCC 亚型。

相似文献

1
TSC/MTOR-mutated eosinophilic renal tumors are a distinct entity that is CK7+/CK20-/vimentin-: a validation study.TSC/MTOR 突变型嗜酸性肾肿瘤是一种独特的实体瘤,其 CK7+/CK20-/波形蛋白-:一项验证性研究。
Hum Pathol. 2021 Sep;115:84-95. doi: 10.1016/j.humpath.2020.12.006. Epub 2020 Dec 22.
2
Eosinophilic Renal Cell Tumors With a TSC and MTOR Gene Mutations Are Morphologically and Immunohistochemically Heterogenous: Clinicopathologic and Molecular Study.伴有 TSC 和 MTOR 基因突变的嗜酸性肾细胞肿瘤在形态学和免疫组织化学上具有异质性:临床病理和分子研究。
Am J Surg Pathol. 2020 Jul;44(7):943-954. doi: 10.1097/PAS.0000000000001457.
3
"Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.“伴平滑肌样基质的肾细胞癌”存在 TSC1、TSC2、MTOR 和/或 ELOC(TCEB1)体细胞突变:18 例散发性肿瘤的临床病理和分子特征支持其为一种独特实体。
Am J Surg Pathol. 2020 May;44(5):571-581. doi: 10.1097/PAS.0000000000001422.
4
Somatic Mutations of TSC2 or MTOR Characterize a Morphologically Distinct Subset of Sporadic Renal Cell Carcinoma With Eosinophilic and Vacuolated Cytoplasm.TSC2 或 MTOR 的体细胞突变特征是具有嗜酸性和空泡状细胞质的散发性肾细胞癌的形态学上明显不同的亚群。
Am J Surg Pathol. 2019 Jan;43(1):121-131. doi: 10.1097/PAS.0000000000001170.
5
Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome.嫌色细胞肾细胞癌的分子特征揭示了不良预后患者 mTOR 通路的改变。
Mod Pathol. 2020 Dec;33(12):2580-2590. doi: 10.1038/s41379-020-0607-z. Epub 2020 Jul 2.
6
Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations: Molecular Analysis Supports an Expanding Clinicopathologic Spectrum.嗜酸性实体和囊性(ESC)肾细胞癌存在 TSC 突变:分子分析支持扩展的临床病理谱。
Am J Surg Pathol. 2018 Sep;42(9):1166-1181. doi: 10.1097/PAS.0000000000001111.
7
Low-grade oncocytic tumor of kidney harboring TSC/MTOR mutation: clinicopathologic, immunohistochemical and molecular characteristics support a distinct entity.携带TSC/MTOR突变的肾脏低级别嗜酸性细胞瘤:临床病理、免疫组化及分子特征支持其为一种独特的实体瘤。
Virchows Arch. 2022 May;480(5):999-1008. doi: 10.1007/s00428-022-03283-x. Epub 2022 Jan 31.
8
Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma.嗜酸性实体和囊性肾细胞癌中 TSC 基因的种系双等位基因缺失。
Eur Urol. 2018 Oct;74(4):483-486. doi: 10.1016/j.eururo.2018.06.007. Epub 2018 Jun 23.
9
Renal Cell Carcinoma in Tuberous Sclerosis Complex.结节性硬化症相关肾细胞癌。
Genes (Basel). 2021 Oct 8;12(10):1585. doi: 10.3390/genes12101585.
10
TSC/MTOR -associated Eosinophilic Renal Tumors Exhibit a Heterogeneous Clinicopathologic Spectrum : A Targeted Next-generation Sequencing and Gene Expression Profiling Study.与结节性硬化症/哺乳动物雷帕霉素靶蛋白相关的嗜酸性肾肿瘤具有异质性临床病理谱:一项靶向二代测序和基因表达谱研究
Am J Surg Pathol. 2022 Nov 1;46(11):1562-1576. doi: 10.1097/PAS.0000000000001955. Epub 2022 Aug 19.

引用本文的文献

1
Eosinophilic Solid and Cystic Renal Cell Carcinoma-A Systematic Review and Meta-Analysis.嗜酸性实性和囊性肾细胞癌的系统评价和荟萃分析。
Int J Mol Sci. 2024 May 30;25(11):5982. doi: 10.3390/ijms25115982.
2
L1 Cell Adhesion Molecule (L1CAM) Expression and Molecular Alterations Distinguish Low-Grade Oncocytic Tumor From Eosinophilic Chromophobe Renal Cell Carcinoma.L1细胞黏附分子(L1CAM)表达及分子改变可区分低级别嗜酸细胞瘤与嗜酸性嫌色肾细胞癌。
Mod Pathol. 2024 May;37(5):100467. doi: 10.1016/j.modpat.2024.100467. Epub 2024 Mar 7.
3
Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT.
评价一组肾脏低级别嗜酸细胞瘤(LOT)的机构系列,并回顾 LOT 的突变景观。
Virchows Arch. 2023 Nov;483(5):687-698. doi: 10.1007/s00428-023-03673-9. Epub 2023 Oct 17.
4
Recent Advances in Renal Tumors with TSC/mTOR Pathway Abnormalities in Patients with Tuberous Sclerosis Complex and in the Sporadic Setting.结节性硬化症患者及散发性病例中伴有TSC/mTOR通路异常的肾肿瘤的最新进展
Cancers (Basel). 2023 Aug 10;15(16):4043. doi: 10.3390/cancers15164043.
5
Are Renal Cell Carcinoma with Fibromyomatous Stroma (RCC-FMS) and Thyroid-like Follicular Carcinoma of the Kidney (TLFCK) Really Independent Variants?伴纤维肌瘤样间质的肾细胞癌(RCC-FMS)和肾甲状腺样滤泡癌(TLFCK)真的是独立的病理类型吗?
Diagnostics (Basel). 2022 Dec 28;13(1):86. doi: 10.3390/diagnostics13010086.
6
TSC/mTOR Pathway Mutation Associated Eosinophilic/Oncocytic Renal Neoplasms: A Heterogeneous Group of Tumors with Distinct Morphology, Immunohistochemical Profile, and Similar Genetic Background.结节性硬化症/哺乳动物雷帕霉素靶蛋白(TSC/mTOR)通路突变相关的嗜酸性/嗜酸性粒细胞性肾肿瘤:一组具有不同形态、免疫组织化学特征和相似遗传背景的异质性肿瘤。
Biomedicines. 2022 Jan 29;10(2):322. doi: 10.3390/biomedicines10020322.
7
Low-grade oncocytic tumor (LOT) - a new renal entity ready for a prime time: An updated review.低级别嗜酸细胞瘤(LOT)- 一种准备崭露头角的新型肾脏实体瘤:更新综述。
Histol Histopathol. 2022 May;37(5):405-413. doi: 10.14670/HH-18-435. Epub 2022 Feb 14.
8
Low-grade oncocytic tumor of kidney harboring TSC/MTOR mutation: clinicopathologic, immunohistochemical and molecular characteristics support a distinct entity.携带TSC/MTOR突变的肾脏低级别嗜酸性细胞瘤:临床病理、免疫组化及分子特征支持其为一种独特的实体瘤。
Virchows Arch. 2022 May;480(5):999-1008. doi: 10.1007/s00428-022-03283-x. Epub 2022 Jan 31.
9
Renal Cell Carcinoma in Tuberous Sclerosis Complex.结节性硬化症相关肾细胞癌。
Genes (Basel). 2021 Oct 8;12(10):1585. doi: 10.3390/genes12101585.
10
Germline and sporadic mTOR pathway mutations in low-grade oncocytic tumor of the kidney.肾脏低级别嗜酸细胞瘤中的种系和散发性 mTOR 通路突变。
Mod Pathol. 2022 Mar;35(3):333-343. doi: 10.1038/s41379-021-00896-6. Epub 2021 Sep 20.